TargetMol

Flecainide acetate

Product Code:
 
TAR-T7219
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7219-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7219-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7219-25mg25mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7219-50mg50mg£183.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7219-100mg100mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Flecainide (acetate) is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias (abnormal fast rhythms of the heart).
CAS:
54143-56-5
Formula:
C19H24F6N2O5
Molecular Weight:
474.4
Pathway:
Membrane transporter/Ion channel
Purity:
0.9991
SMILES:
CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1
Target:
Sodium Channel

References

Jean-Fran?ois Desaphy, Luca A D , Didonna M P , et al. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block[J]. The Journal of Physiology, 2004, 554(Pt 2):321-334. Kohli, Vikas. Oral flecainide is effective in management of refractory tachycardia in infants[J]. Indian Heart Journal, 2013, 65(2):168-171.